Skip to content

Cyclophotocoagulation in Primary Open Angle Glaucoma

Low Power Continuous Wave Versus Micro Pulse Diode Versus High Intensity Focused Ultrasound Cyclophotocoagulation in Primary Open Angle Glaucoma

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04430296
Enrollment
78
Registered
2020-06-12
Start date
2020-08-01
Completion date
2021-08-01
Last updated
2020-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Open Angle Glaucoma

Brief summary

The use of Cyclodestruction procedures has been extended to patients with non-refractory glaucoma and good vision. Our aim is to compare the safety and efficacy of three cyclodestructive treatments; High Intensity Focused Ultrasound (HIFU) Cyclocoagulation versus micropulse cyclophotocoagulation (MP-CPC) versus transscleral continuous wave cyclophotocoagulation (CW-CPC) for the treatment of Primary open angle glaucoma.

Interventions

High Intensity Focused Ultrasound Cyclophotocoagulation (HIFU): parameters: 21 MHz frequency, 2.45 W acoustic power, with the activation of each transducer lasting 6 seconds MicroPulse cyclophotocoagulation (MP-CPC):Laser settings of 2 Watts (W) will be applied for a 90 seconds treatment time for each 180 degrees, with a duty cycle of 31.3%, which consists of 0.5ms on time and 1.1 ms off-time and delivering a total of 112,7 Joules Continuous Wave cyclophotocoagulation (CW-CPC): The laser settings used will be 1.250 W, 4s exposure time per burn, 22-24 burns per eye.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* medically uncontrolled, primary open angle glaucoma attending glaucoma clinic

Exclusion criteria

* patients with history of previous laser or surgical intervention

Design outcomes

Primary

MeasureTime frameDescription
Success rate.6 monthsThe success will be defined as IOP between 6 and 21 mmHg and at least a 30% reduction in IOP with or without topical IOP lowering medications.

Secondary

MeasureTime frame
Frequency of complications6 months

Contacts

Primary ContactAhmed M Abdelrahman, MD
ahmed.mostafa@kasralainy.edu.eg00201227394861
Backup ContactHeba M ElSaied, MD
hebamagdy13@yahoo.com00201224645060

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026